What's Going On With BioCryst Stock After Earnings?

BioCryst Pharmaceuticals, Inc. BCRX shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell.

The Details:

BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share from the same period last year. 

The company reported quarterly sales of $93.4 million which beat the analyst consensus estimate of $90.01 million by 3.77% and is a 17.42% increase over sales of $79.55 million from the prior year's quarter. 

BioCryst sees fiscal year 2024 Orladeyo net revenue of between $380 million and $400 million. The company said that it expects an operating profit in 2024 and to be approaching positive earnings per share and positive cash flow in the second half of 2025.

“The impressive growth we are seeing with ORLADEYO has put us in a position to accelerate our path to profitability while continuing to invest in our diverse pipeline of first-in-class or best-in-class molecules that we believe will deliver our next marketed product,” said Jon Stonehouse, CEO of BioCryst.

BioCryst said the total number of U.S. patients on paid or long-term free product reached 1,104 at the end of the fourth quarter and net U.S. patient growth totaled 321 in 2023. 

Related News: Wedbush’s Dan Ives Says ‘AI Party Just Starting’

Is BCRX A Good Stock To Buy?

Wall Street analysts view BioCryst Pharma on the whole as a Buy, given the history of coverage over the past three months. Serge Belanger from Needham in BioCryst Pharma is the most optimistic.

But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, BioCryst Pharma rose 8.74%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 17.42% over the past year.

A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.

BCRX Price Action: According to Benzinga Pro, BioCryst shares are up 0.49% at $5.738 at the time of publication.

Image: Volodymyr Hryshchenko from Unsplash